KLEIN JOSEPH III 4
4 · IONIS PHARMACEUTICALS INC · Filed Apr 2, 2026
Research Summary
AI-generated summary of this filing
Ionis (IONS) Director Joseph Klein III Exercises Options, Sells Shares
What Happened Joseph Klein III, a director of Ionis Pharmaceuticals (IONS), exercised a total of 22,321 option-derived shares on April 1, 2026 (two exercises: 12,000 at $38.06 and 10,321 at $41.08; exercise cost $880,707) and sold those 22,321 shares the same day in open-market transactions for total proceeds of $1,686,302. The exercises and immediate sales effectively resulted in net cash proceeds of approximately $805,595. The sales were made pursuant to a pre-established Rule 10b5-1 trading plan.
Key Details
- Transaction date: April 1, 2026; Form filed April 2, 2026 (timely).
- Option exercises (Code M): 12,000 shares @ $38.06 = $456,720; 10,321 shares @ $41.08 = $423,987 (total exercise cost $880,707).
- Open-market sales (Code S): 20,105 shares at weighted avg $75.50 (prices ranged $74.865–$75.85) = $1,517,988; 2,216 shares at weighted avg $75.95 (prices ranged $75.88–$76.17) = $168,314 (total proceeds $1,686,302).
- Net proceeds (sales minus exercise costs): ~$805,595.
- Footnotes: sales executed under a 10b5-1 plan adopted Nov 26, 2025 (F1); weighted-average price ranges disclosed (F2, F3); reporting person disclaims beneficial ownership of securities held by his son (F4).
- Shares owned after the transactions are not specified in the provided filing excerpt.
Context These entries show option exercises followed by immediate open-market sales — commonly a cashless exercise pattern (exercise then sell). The 10b5-1 plan note indicates the sales were executed under a prearranged trading plan, which is routine and intended to avoid accusations of opportunistic timing. This filing is factual disclosure of the transactions and does not by itself indicate the insider’s future view of the company.
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-04-01$38.06/sh+12,000$456,720→ 23,014 total - Exercise/Conversion
Common Stock
2026-04-01$41.08/sh+10,321$423,987→ 33,335 total - Sale
Common Stock
[F1][F2]2026-04-01$75.50/sh−20,105$1,517,988→ 13,230 total - Sale
Common Stock
[F1][F3]2026-04-01$75.95/sh−2,216$168,314→ 11,014 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-04-01−12,000→ 0 totalExercise: $38.06From: 2023-07-01Exp: 2032-06-30→ Common Stock (12,000 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-04-01−10,321→ 0 totalExercise: $41.08From: 2024-07-03Exp: 2033-07-02→ Common Stock (10,321 underlying)
- 100(indirect: by Son)
Common Stock
[F4]
Footnotes (4)
- [F1]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 26, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.865 to $75.85 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.88 to $76.17 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
- [F4]The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.